| Firm | Analyst |
|---|---|
| Canaccord Genuity | John Newman, Ph.D. |
| Cowen & Co. | Phil Nadeau, Ph.D. |
| Marc Frahm, Ph.D. | |
| Evercore ISI | Jonathan Miller, Ph.D. |
| Michael DiFiore, Pharm.D. | |
| Goldman Sachs | Salveen Richter |
| H.C. Wainwright | Robert Burns |
| Mizuho Securities | Salim Syed |
| Stifel | Benjamin Burnett, Ph.D. |
Atara Biotherapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Atara Biotherapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Atara Biotherapeutics or its management. Atara Biotherapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.